Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 in HER2-positive gastric or gastroesophageal junction cancer
NCT06532006Phase 3Recruiting
- Sponsor
- Henlius
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of hlx22 in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Henlius. Started Nov 2024; status: recruiting.
02
Drugs
hlx22
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06532006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532006.